Figure 1 Flow chart of the studies considered and finally selected for review.
Figure 2 Neuraminidase inhibitor exposure during pregnancy and the risk of congenital malformations in the offspring.
Figure 3 Neuraminidase inhibitor exposure during pregnancy and the risk of adverse neonatal outcomes in the offspring (A) low birth weight (B) low Apgar score (C) SGA (D) preterm birth.